Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs TKNO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TKNO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

TKNO Overall Winner 6-Pillar Tally: TLPH 1 – 4 TKNO (1 Tie) Matrix Metrics: TLPH 4 – 6 TKNO

As of Nov 16, 2026, Alpha Teknova, Inc. (TKNO) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas TKNO carries 37.6/100 (SELL) at $7.90 (N/M Forward P/E, -31.6% operating margin).

  • Defensive Composite Rating Caution: Although TKNO compares more favorably head-to-head, both TLPH (37.1/100 SELL) and TKNO (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile TKNO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs TKNO
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
TKNO NASDAQ Head-to-Head Winner
Alpha Teknova, Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$7.90
-3.78% 1D
Market Cap $521.8M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 1.19β · 114% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 5.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 51
RSI-14: 50.9 · SMA20: $7.53 · SMA50: $7.87

6-Pillar Scorecard Institutional Category Breakdown (TLPH 1 – 4 TKNO)

Columns: Metric · TLPH · TKNO
1. Valuation Multiples TLPH
Forward P/E 1.0x N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 11.4x
2. Growth & Scale TKNO
Revenue Growth (YoY) +0.0% +21.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $46M
Market Cap $53.7M $521.8M
3. Profitability & Quality TKNO
Gross Margin N/A 36.4%
Operating Margin -1474700.0% -31.6%
Net Profit Margin 0.0% -34.8%
Return on Equity (ROE) -143.4% -24.1%
4. Balance Sheet & Cash Flow TKNO
Cash Generation (TTM) -$15M EBITDA -$8.2M EBITDA
Cash Flow Margin N/A -17.8% EBITDA Mgn
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $1.11 Book/Sh · -24.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 118.4% (100th %ile) 10.6% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat TKNO
OpEx & R&D Intensity N/A 68.0% of Rev ($31M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (4) vs TKNO (6)
Institutional Metric TLPH TKNO Criterion Row Edge
Market Capitalization
Scale
$53.7M $521.8M Larger Scale TKNO
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +21.5% Higher Growth TKNO
Operating Margin (TTM)
Profitability
-1474700.0% -31.6% Higher Margin TKNO
Net Profit Margin
Profitability
0.0% -34.8% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-143.4% -24.1% Higher ROE TKNO
52-Week Range Position
Momentum
20% ($1–$2) 79% ($2–$9) Stronger Trend TKNO
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 1.19β · 114% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 37.6 / 100 (SELL) Higher Composite TKNO
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 36.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 11.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) -$8.2M EBITDA ($1.11 Book/Sh · -24.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TKNO +31.87 pp
TLPH: -20.29% · TKNO: +11.58%
3M Horizon TKNO +44.86 pp
TLPH: -28.85% · TKNO: +16.01%
6M Horizon TKNO +110.25 pp
TLPH: +7.98% · TKNO: +118.23%
1Y Horizon TKNO +96.34 pp
TLPH: -18.01% · TKNO: +78.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs TKNO. Trailing 12-month operating profitability (TLPH -1474700.0% vs TKNO -31.6%) and valuation multiples (TLPH 1.0x vs TKNO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
TKNO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin36.4%
Op. Margin-31.6%
ROE / Fwd P/E-24.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TKNO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 10.6%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TKNO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TKNO Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $521.8M market capitalization and -31.6% operating margin.
OpEx & R&D Reinvestment 68.0% of Rev ($31M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs TKNO Key Questions & Quantitative Answers

As of Nov 16, 2026, Alpha Teknova, Inc. (TKNO) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas TKNO carries 37.6/100 (SELL) at $7.90 (N/M Forward P/E, -31.6% operating margin). Defensive Composite Rating Caution: Although TKNO compares more favorably head-to-head, both TLPH (37.1/100 SELL) and TKNO (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile TKNO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TKNO leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with TKNO at +21.5% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (36.4% gross margin, -31.6% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $46M for TKNO. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 68.0% of Rev ($31M) (0 disclosures) for TKNO.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas TKNO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.4x EV/Revenue (-17.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus TKNO (-24.1% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, TKNO carries 10.6% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.